CD19 and hepatocellular carcinoma: Clinical studies have further demonstrated that the CD19+IL-10+ Bregs in hepatocellular carcinoma (HCC) patients are significantly lower than those in healthy donors and patients with chronic hepatitis B infection before surgery, but they dramatically increase and remain high after surgery (about seven days after surgery, p < 0.05) [59].